Literature DB >> 23712522

Changes in endolysosomal enzyme activities in cerebrospinal fluid of patients with Parkinson's disease.

Karin D van Dijk1, Emanuele Persichetti, Davide Chiasserini, Paolo Eusebi, Tommaso Beccari, Paolo Calabresi, Henk W Berendse, Lucilla Parnetti, Wilma D J van de Berg.   

Abstract

Parkinson's disease (PD) is characterized neuropathologically by the cytoplasmic accumulation of misfolded α-synuclein in specific brain regions. The endolysosomal pathway appears to be involved in α-synuclein degradation and, thus, may be relevant to PD pathogenesis. This assumption is further strengthened by the association between PD and mutations in the gene encoding for the lysosomal hydrolase glucocerebrosidase. The objective of the present study was to determine whether endolysosomal enzyme activities in cerebrospinal fluid (CSF) differ between PD patients and healthy controls. Activity levels of 6 lysosomal enzymes (β-hexosaminidase, α-fucosidase, β-mannosidase, β-galactosidase, β-glucocerebrosidase, and cathepsin D) and 1 endosomal enzyme (cathepsin E) were measured in CSF from 58 patients with PD (Hoehn and Yahr stages 1-3) and 52 age-matched healthy controls. Enzyme activity levels were normalized against total protein levels. Normalized cathepsin E and β-galactosidase activity levels were significantly higher in PD patients compared with controls, whereas normalized α-fucosidase activity was reduced. Other endolysosomal enzyme activity levels, including β-glucocerebrosidase activity, did not differ significantly between PD patients and controls. A combination of normalized α-fucosidase and β-galactosidase discriminated best between PD patients and controls with sensitivity and specificity values of 63%. In conclusion, the activity of a number of endolysosomal enzymes is changed in CSF from PD patients compared with healthy controls, supporting the alleged role of the endolysosomal pathway in PD pathogenesis. The usefulness of CSF endolysosomal enzyme activity levels as PD biomarkers, either alone or in combination with other markers, remains to be established in future studies.
Copyright © 2013 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23712522     DOI: 10.1002/mds.25495

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  37 in total

Review 1.  Biomarkers of Parkinson's disease: 20 years later.

Authors:  Rezzak Yilmaz; Franziska Hopfner; Thilo van Eimeren; Daniela Berg
Journal:  J Neural Transm (Vienna)       Date:  2019-04-04       Impact factor: 3.575

2.  MicroRNA-217/138-5p downregulation inhibits inflammatory response, oxidative stress and the induction of neuronal apoptosis in MPP+-induced SH-SY5Y cells.

Authors:  Mingda Wang; Hongming Sun; Yina Yao; Xicun Tang; Bo Wu
Journal:  Am J Transl Res       Date:  2019-10-15       Impact factor: 4.060

3.  Global, in situ analysis of the structural proteome in individuals with Parkinson's disease to identify a new class of biomarker.

Authors:  Marie-Therese Mackmull; Luise Nagel; Fabian Sesterhenn; Jan Muntel; Jan Grossbach; Patrick Stalder; Roland Bruderer; Lukas Reiter; Wilma D J van de Berg; Natalie de Souza; Andreas Beyer; Paola Picotti
Journal:  Nat Struct Mol Biol       Date:  2022-10-12       Impact factor: 18.361

4.  Network and Pathway-Based Analyses of Genes Associated with Parkinson's Disease.

Authors:  Yanshi Hu; Zhenhua Pan; Ying Hu; Lei Zhang; Ju Wang
Journal:  Mol Neurobiol       Date:  2016-06-27       Impact factor: 5.590

5.  Cellular senescence in aging and age-related diseases: Implications for neurodegenerative diseases.

Authors:  Erin O Wissler Gerdes; Yi Zhu; B Melanie Weigand; Utkarsh Tripathi; Terence C Burns; Tamar Tchkonia; James L Kirkland
Journal:  Int Rev Neurobiol       Date:  2020-08-11       Impact factor: 3.230

6.  Correlation between decreased CSF α-synuclein and Aβ₁₋₄₂ in Parkinson disease.

Authors:  Chandana Buddhala; Meghan C Campbell; Joel S Perlmutter; Paul T Kotzbauer
Journal:  Neurobiol Aging       Date:  2014-08-04       Impact factor: 4.673

Review 7.  Are there roles for brain cell senescence in aging and neurodegenerative disorders?

Authors:  Florence C C Tan; Emmette R Hutchison; Erez Eitan; Mark P Mattson
Journal:  Biogerontology       Date:  2014-10-11       Impact factor: 4.277

8.  Alpha galactosidase A activity in Parkinson's disease.

Authors:  R N Alcalay; P Wolf; O A Levy; U J Kang; C Waters; S Fahn; B Ford; S H Kuo; N Vanegas; H Shah; C Liong; S Narayan; M W Pauciulo; W C Nichols; Z Gan-Or; G A Rouleau; W K Chung; P Oliva; J Keutzer; K Marder; X K Zhang
Journal:  Neurobiol Dis       Date:  2018-02-02       Impact factor: 5.996

Review 9.  Vesicle trafficking and lipid metabolism in synucleinopathy.

Authors:  Saranna Fanning; Dennis Selkoe; Ulf Dettmer
Journal:  Acta Neuropathol       Date:  2020-06-30       Impact factor: 17.088

Review 10.  Alpha-Synuclein as a Biomarker of Parkinson's Disease: Good, but Not Good Enough.

Authors:  Upasana Ganguly; Sukhpal Singh; Soumya Pal; Suvarna Prasad; Bimal K Agrawal; Reena V Saini; Sasanka Chakrabarti
Journal:  Front Aging Neurosci       Date:  2021-07-08       Impact factor: 5.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.